Ketamine-Assisted Psychotherapy for PTSD Related to Racial Discrimination
This case study of ketamine (4x) in combination with psychotherapy (mindfulness-based cognitive therapy, MBCT) describes how it was used to treat PTSD symptoms. The study shows initial success, but also remission at 6-month follow-up.
Authors
- Thomas Williams
- Monnica Williams
- Sara Reed
Published
Abstract
Current research suggests that ketamine-assisted psychotherapy has benefit for the treatment of mental disorders. We report on the results of ketamine-assisted intensive outpatient psychotherapeutic treatment of a client with treatment-resistant, posttraumatic stress disorder (PTSD) as a result of experiences of racism and childhood sexual abuse. The client’s presenting symptoms included hypervigilance, social avoidance, feelings of hopelessness, and intense recollections. These symptoms impacted all areas of daily functioning. Psychoeducation was provided on how untreated intergenerational trauma, compounded by additional traumatic experiences, potentiated the client’s experience of PTSD and subsequent maladaptive coping mechanisms. Ketamine was administered four times over a 13-day span as an off-label, adjunct to psychotherapy. Therapeutic interventions and orientations utilized were mindfulnessbased cognitive therapy (MBCT) and functional analytic psychotherapy (FAP). New skills were obtained in helping the client respond effectively to negative self-talk, catastrophic thinking, and feelings of helplessness. Treatment led to a significant reduction in symptoms after completion of the program, with gains maintained 4months post-treatment. This case study demonstrates the effective use of ketamine as an adjunct to psychotherapy in treatment-resistant PTSD.
Research Summary of 'Ketamine-Assisted Psychotherapy for PTSD Related to Racial Discrimination'
Introduction
Over the last decade there has been renewed clinical and research interest in psychedelic-assisted psychotherapies for conditions such as depression, anxiety, substance use disorders, obsessive–compulsive disorder and post‑traumatic stress disorder (PTSD). The paper situates ketamine within this broader trend, noting that single ketamine infusions can produce rapid antidepressant and anti‑suicidal effects and that ketamine has been examined as an adjunct to psychotherapy. The authors also highlight that much prior psychedelic research has under‑represented people of colour, and that racial trauma — including overt acts of discrimination and more subtle microaggressions — can contribute to PTSD symptoms yet is contested in diagnostic and treatment literatures. This case report describes an intensive outpatient ketamine‑assisted psychotherapy (KAP) programme delivered to a 58‑year‑old African American woman with complex, treatment‑resistant PTSD arising from childhood sexual abuse and repeated race‑based discrimination at work. The paper aims to document the treatment procedures, culturally informed therapeutic adaptations, clinical outcomes across symptom measures and functioning, and practical considerations for clinicians working with clients of colour in KAP contexts.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- Authors
- APA Citation
Halstead, M., Reed, S., Krause, R., & Williams, M. T. (2021). Ketamine-Assisted Psychotherapy for PTSD Related to Racial Discrimination. Clinical Case Studies, 20(4), 310-330. https://doi.org/10.1177/1534650121990894
References (11)
Papers cited by this study that are also in Blossom
Berman, R. M., Cappiello, A., Anand, A. et al. · Biological Psychiatry (2000)
Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S. et al. · Journal of Psychopharmacology (2016)
Diazgranados, N., Ibrahim, L., Brutsche, N. E. et al. · JAMA Psychiatry (2010)
Feder, A., Costi, S., Rutter, S. B. et al. · American Journal of Psychiatry (2021)
Feder, A., Parides, M. K., Murrough, J. W. · JAMA Psychiatry (2014)
Liriano, F., Hatten, C., Schwartz, T. M. · Drugs In Context (2019)
Luoma, J. B., Chwyl, C., Bathje, G. J. et al. · Journal of Psychoactive Drugs (2020)
Mithoefer, M. C., Feduccia, A. A., Jerome, L. et al. · Psychopharmacology (2019)
Chen, X., Hou, X., Bai, D. et al. · American Journal of Psychiatry (2019)
Williams, T. M., Davis, A. K., Xin, Y. et al. · Drugs Education Prevention and Policy (2020)
Show all 11 referencesShow fewer
Williams, M. T., Reed, S., George, J. · Journal of Psychedelic Studies (2021)
Cited By (3)
Papers in Blossom that reference this study
de la Salle, S., Gran-Ruaz, S., Davis, A. K. et al. · Canadian Psychology (2022)
Ragnhildstveit, A., Slayton, M., Jackson, L. K. et al. · Brain Sciences (2022)
Smith, D., Faber, S., Buchanan, N. T. et al. · Frontiers in Psychiatry (2022)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.